Gene therapy breakthrough? new trial targets Wilson's disease
NCT ID NCT07173933
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This early-stage trial tests a one-time gene therapy called GC310 for Wilson's disease, a genetic condition that causes copper buildup. About 15 adults will receive a single IV dose and be monitored for a year to check safety and whether it improves copper levels and liver function. The goal is to find the right dose and see if the treatment can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College
Beijing, 100005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.